Health Care & Life Sciences » Pharmaceuticals | Seoul Pharma Co. Ltd.

Seoul Pharma Co. Ltd. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
164
3,918
9,376
9,669
4,427
Total Accounts Receivable
14,625
16,003
14,545
21,784
30,984
Inventories
5,147
4,777
5,997
5,758
4,922
Other Current Assets
35
79
105
167
172
Total Current Assets
19,971
24,778
30,022
37,378
40,505
Net Property, Plant & Equipment
45,619
47,864
47,523
51,433
42,757
Total Investments and Advances
421
1,017
1,044
539
279
Intangible Assets
4,464
4,493
2,910
1,564
1,282
Other Assets
479
-
-
1,110
495
Total Assets
71,423
78,979
82,675
92,541
86,932
ST Debt & Current Portion LT Debt
10,351
14,834
18,080
6,427
12,218
Accounts Payable
3,839
3,027
3,188
3,131
3,010
Income Tax Payable
16
1,006
43
126
297
Other Current Liabilities
2,108
3,532
2,566
2,265
2,914
Total Current Liabilities
16,314
22,400
23,878
11,950
18,439
Long-Term Debt
18,937
20,802
19,689
33,730
9,778
Provision for Risks & Charges
3,920
4,677
5,580
4,786
4,860
Deferred Taxes
468
827
1,176
516
1,614
Other Liabilities
-
-
-
5
-
Total Liabilities
39,171
47,879
49,147
50,471
33,076
Common Equity (Total)
32,252
31,100
33,528
42,070
53,856
Total Shareholders' Equity
32,252
31,100
33,528
42,070
53,856
Total Equity
32,252
31,100
33,528
42,070
53,856
Liabilities & Shareholders' Equity
71,423
78,979
82,675
92,541
86,932

About Seoul Pharma Co.

View Profile
Address
124-31 Osongsaengmyeong 6-ro
Cheongju NC 28158
Korea, Republic Of
Employees -
Website http://www.seoulpharma.com
Updated 09/14/2018
Seoul Pharma Co., Ltd. engages in the manufacturing and distribution of pharmaceuticals. Its products include drugs for cardiovascular system, respiratory and digestive system, antipyretic, analgesic, anti-inflammatory, antibacterial, anti-fungal, anti-viral, cream and ointment, anti-diabetic, anti-obesity, tonics, vitamins and minerals. The company was founded in 1976 and is headquartered in Cheongju, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.